Trials / Recruiting
RecruitingNCT06051760
NV-001 in the Treatment of Advanced Solid Tumors
A Phase I Study to Explore the Safety and Efficacy of NV-001 in the Treatment of Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.
Detailed description
This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors. The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol to get preliminary safety and efficacy evidence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NV-001 | NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells. |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2025-03-01
- Completion
- 2025-06-01
- First posted
- 2023-09-25
- Last updated
- 2025-02-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06051760. Inclusion in this directory is not an endorsement.